|
![]() |
|||
|
||||
OverviewThis book introduces readers to Direct Acting Antiviral (DAAs) agents, newly developed drugs to treat chronic hepatitis C virus infection, which have an excellent anti-viral effect on virus replication. These drugs have been developed to enhance the effect of interferon and ribavirin, as the resistant strains against each drug have been described both in vitro and in vivo and the existences of naturally occurring variants have been reported. However, since the combination of different classes of DAAs is sufficient to completely eradicate the virus without the need for interferon or ribavirin, the current treatment regimen does not include interferon. Ribavirin is used in combination with sofosbuvir, a potent polymerase inhibitor, to enhance its antiviral effects. Hepatitis C Virus Treatment offers readers a comprehensive guide to hepatitis C; describing the resistance profiles against these drugs and shedding light on the difficulties involved in DAA therapy and the direction of future treatments, it will equip doctors to understand the essentials of treating the disease. It also describes in detail new and innovative DAA treatments, the effects of the agents, and the characteristics of resistance, providing cutting-edge information not only for hepatologists, but also for researchers, clinical residents, and medical students. Full Product DetailsAuthor: Kazuaki ChayamaPublisher: Springer Verlag, Singapore Imprint: Springer Verlag, Singapore Edition: Softcover reprint of the original 1st ed. 2017 Weight: 0.454kg ISBN: 9789811096105ISBN 10: 9811096104 Pages: 75 Publication Date: 05 July 2018 Audience: Professional and scholarly , Professional & Vocational Format: Paperback Publisher's Status: Active Availability: Manufactured on demand ![]() We will order this item for you from a manufactured on demand supplier. Table of ContentsPreface The first generation protease inhibitor Telaprevir and the emergence of antiviral resistance Features of the second wave of the first generation protease inhibitors: effect and tolerance Effects and resistance risks of combination treatment with Daclatasvir + Asunaprevir: the first approved oral agent without IFN and ribavirin Resistance features of NS5A inhibitors and methods for detection Detection of naturally occurring variants with resistance features against antiviral drugs Incidence and characteristics of naturally occurring resistant strains Characteristics and resistance profiles of polymerase inhibitors Emerging antivirals in the futureReviewsAuthor InformationProf. Kazuaki ChayamaDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University Tab Content 6Author Website:Countries AvailableAll regions |